SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: bob zagorin12/1/2004 10:39:07 AM
   of 3044
 
MLNM: FDA Accepts Filing w/ Priority Review for VELCADE [delayed]
Ridgeland, MS, DEC 01, 2004 (EventX/Knobias.com via COMTEX) -- Millennium Pharmaceuticals, Inc. (MLNM) announced the FDA
accepted for review the Company's supplemental New Drug Application and granted Priority Review designation for VELCADE for the
treatment of patients with multiple myeloma who have received at least one prior therapy. The submission was based on data from
the phase III APEX study that compared VELCADE to a traditional myeloma therapy, high-dose dexamethasone, which demonstrated
a statistically significant survival in patients receiving VELCADE. A patient population of approximately 22,000 in the U.S. could
potentially benefit from a new second-line treatment MLNM: FDA Accepts Filing w/ Priority Review for VELCADE [delayed]
Ridgeland, MS, DEC 01, 2004 (EventX/Knobias.com via COMTEX) -- Millennium Pharmaceuticals, Inc. (MLNM) announced the FDA
accepted for review the Company's supplemental New Drug Application and granted Priority Review designation for VELCADE for the
treatment of patients with multiple myeloma who have received at least one prior therapy. The submission was based on data from
the phase III APEX study that compared VELCADE to a traditional myeloma therapy, high-dose dexamethasone, which demonstrated
a statistically significant survival in patients receiving VELCADE. A patient population of approximately 22,000 in the U.S. could
potentially benefit from a new second-line treatment option.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News